CU20090169A7 - Métodos y composiciones para virus vivos atenuados - Google Patents

Métodos y composiciones para virus vivos atenuados

Info

Publication number
CU20090169A7
CU20090169A7 CU20090169A CU20090169A CU20090169A7 CU 20090169 A7 CU20090169 A7 CU 20090169A7 CU 20090169 A CU20090169 A CU 20090169A CU 20090169 A CU20090169 A CU 20090169A CU 20090169 A7 CU20090169 A7 CU 20090169A7
Authority
CU
Cuba
Prior art keywords
compositions
live
viruses
methods
attenuated
Prior art date
Application number
CU20090169A
Other languages
English (en)
Inventor
O'neil Wiggan
Jorge E Osorio
Dan T Stinchcomb
Original Assignee
Inviragen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39827288&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU20090169(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Inviragen Inc filed Critical Inviragen Inc
Publication of CU20090169A7 publication Critical patent/CU20090169A7/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L71/00—Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
    • C08L71/02—Polyalkylene oxides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G2650/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G2650/28—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule characterised by the polymer type
    • C08G2650/58—Ethylene oxide or propylene oxide copolymers, e.g. pluronics
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00—Applications
    • C08L2203/02—Applications for biomedical use
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10061—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16061—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36161—Methods of inactivation or attenuation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Polymers & Plastics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Las formas de realización de la presente se refieren a composiciones y métodos para virus vivos. En ciertas formas de realización, una composición a virus vivo atenuado incluye, sin limitaciones, uno o mas virus vivos atenuados y composiciones para reducir la inactivación y/o degradación del virus vivo atenuado. En otras formas de realización, la composición de virus vivo atenuado puede ser una composición de vacuna. En aún otras composiciones, una composición a virus vivo atenuado puede incluir al menos un hidrato de carbono, al menos una proteína y al menos un agente tensioactivo de alto peso molecular para reducir la inactivación y/o degradación del virus vivo atenuado.
CU20090169A 2007-04-06 2009-10-06 Métodos y composiciones para virus vivos atenuados CU20090169A7 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91057907P 2007-04-06 2007-04-06

Publications (1)

Publication Number Publication Date
CU20090169A7 true CU20090169A7 (es) 2012-06-21

Family

ID=39827288

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20090169A CU20090169A7 (es) 2007-04-06 2009-10-06 Métodos y composiciones para virus vivos atenuados

Country Status (28)

Country Link
US (4) US8084039B2 (es)
EP (2) EP2144998B1 (es)
JP (4) JP5296775B2 (es)
KR (4) KR102134980B1 (es)
CN (4) CN101679954A (es)
AU (1) AU2008279576C1 (es)
BR (1) BRPI0809663B8 (es)
CA (1) CA2720570C (es)
CO (1) CO6260150A2 (es)
CU (1) CU20090169A7 (es)
CY (1) CY1118958T1 (es)
DK (1) DK2144998T3 (es)
ES (1) ES2621511T3 (es)
HK (2) HK1140516A1 (es)
HR (1) HRP20170513T1 (es)
HU (1) HUE031617T2 (es)
IL (3) IL201429A (es)
LT (1) LT2144998T (es)
MX (2) MX360728B (es)
MY (2) MY156422A (es)
NZ (2) NZ580978A (es)
PH (1) PH12015500773A1 (es)
PL (1) PL2144998T3 (es)
PT (1) PT2144998T (es)
SG (2) SG10201508397VA (es)
SI (1) SI2144998T1 (es)
WO (1) WO2009014774A1 (es)
ZA (2) ZA200907790B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102134980B1 (ko) * 2007-04-06 2020-07-16 다케다 백신즈 인코포레이티드 살아있는 약독화된 바이러스를 위한 방법 및 조성물
EP2143440A1 (fr) * 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
US7998488B2 (en) 2008-11-14 2011-08-16 Baxter International Inc. Vaccine formulations and uses thereof
SG10201503671TA (en) * 2008-12-05 2015-06-29 Takeda Vaccines Inc Compositions, methods and uses for inducing viral growth
US9278070B2 (en) 2009-05-18 2016-03-08 Sigmoid Pharma Limited Composition comprising oil drops
EP2464341B1 (en) 2009-08-12 2022-07-06 Sublimity Therapeutics Limited Immunomodulatory compositions comprising a polymer matrix and an oil phase
DK2646052T3 (en) 2010-12-02 2017-07-17 Oncolytics Biotech Inc LYOPHILIZED VIRAL FORMULATIONS
TW201233802A (en) 2010-12-02 2012-08-16 Oncolytics Biotech Inc Liquid viral formulations
RU2013143149A (ru) * 2011-02-24 2015-03-27 Пэксвэкс, Инк. Составы, пригодные для вакцин, получаемых сушкой распылением
KR20140033171A (ko) * 2011-05-26 2014-03-17 글락소스미스클라인 바이오로지칼즈 에스.에이. 비활성화된 뎅기 바이러스 백신
JP6417217B2 (ja) * 2011-06-28 2018-10-31 ロイコケア・アクチェンゲゼルシャフト ウイルスまたは細菌の新規な安定化方法
EP3246400B1 (en) 2012-01-09 2019-10-23 Sanofi Pasteur Biologics, LLC Purification of herpes virus
WO2013177172A2 (en) * 2012-05-21 2013-11-28 Sanofi Pasteur Limited Herpesvirus compositions and related methods
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
US9314519B2 (en) * 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
EP2968515B1 (en) 2013-03-14 2019-05-08 Takeda Vaccines, Inc. Compositions and methods for live, attenuated alphavirus formulations
US9480739B2 (en) 2013-03-15 2016-11-01 Intervet Inc. Bovine virus vaccines that are liquid stable
US9393298B2 (en) 2013-03-15 2016-07-19 Intervet Inc. Liquid stable bovine virus vaccines
AR097762A1 (es) 2013-09-27 2016-04-13 Intervet Int Bv Formulaciones secas de vacunas que son estables a temperatura ambiente
US10588957B2 (en) 2013-10-25 2020-03-17 Leukocare Ag Method for the production of stabile vaccines
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
AR099470A1 (es) 2014-02-17 2016-07-27 Intervet Int Bv Vacunas de virus de aves de corral líquidas
TWI670085B (zh) 2014-02-19 2019-09-01 荷蘭商英特威國際公司 液體穩定之豬病毒疫苗
CN103877565A (zh) * 2014-02-24 2014-06-25 黄淮学院 治疗膀胱癌的基因针剂及其制备方法
EA036036B1 (ru) 2014-11-07 2020-09-16 Сигмойд Фарма Лимитед Композиции, содержащие циклоспорин
KR102549746B1 (ko) * 2014-12-18 2023-07-03 암젠 인크 안정한 동결된 단순 포진 바이러스 제제
JP2018510160A (ja) * 2015-03-20 2018-04-12 ブルーバード バイオ， インコーポレイテッド ベクター製剤
CN104984357B (zh) * 2015-06-02 2018-01-30 长春百克生物科技股份公司 不含明胶的疫苗保护剂组合物及流感减毒活疫苗
TWI569806B (zh) * 2015-06-10 2017-02-11 輔英科技大學 Stabilizer compositions for vaccines and methods for their preparation and swine fever vaccine containing the same
CN108135995A (zh) * 2015-09-30 2018-06-08 万能药生物有限公司 稳定的活的减毒重组登革疫苗
WO2017109698A1 (en) * 2015-12-22 2017-06-29 Glaxosmithkline Biologicals Sa Immunogenic formulation
AR107262A1 (es) * 2016-01-27 2018-04-11 Lilly Co Eli Inactivación de patógenos por delipidación
US20190100724A1 (en) * 2016-02-18 2019-04-04 Keio University Cell culture medium, culture method, and organoid
CA3021073A1 (en) 2016-04-14 2017-10-19 Trizell Ltd. Viral vector stabilization
CN105925541A (zh) * 2016-05-13 2016-09-07 云南省畜牧兽医科学院 一种蓝舌病病毒冻存保护剂及冻存方法
TWI766876B (zh) * 2016-08-03 2022-06-11 美商武田疫苗股份有限公司 用於與經改良之調配物一起穩定黃病毒的組成物及方法
CA3062549A1 (en) * 2017-05-15 2018-11-22 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
CN107475204A (zh) * 2017-08-03 2017-12-15 中国人民解放军军事医学科学院军事兽医研究所 一种囊膜病毒保护剂及其制备方法
CN107233576B (zh) * 2017-08-08 2020-02-07 江苏省农业科学院 耐热保护剂、猪瘟可室温保存活疫苗及其制备方法和应用
BR112020008482A8 (pt) * 2017-11-01 2023-01-31 Merck Sharp & Dohme Composto leuco
MX2020005857A (es) 2017-12-07 2020-09-09 Merck Sharp & Dohme Formulaciones de composiciones de vacuna contra el virus del dengue.
EP3847246A1 (en) * 2018-09-06 2021-07-14 Bavarian Nordic A/S Storage improved poxvirus compositions
US20220193222A1 (en) * 2018-11-30 2022-06-23 Vaccine Stabilization Institute Viral formulations containing amino acids
US20210322542A1 (en) * 2020-04-11 2021-10-21 Qiyi Xie Vaccination against coronavirus with poliomyelitis vaccine
WO2022037248A1 (en) * 2020-08-19 2022-02-24 Versitech Limited Live attenuated sars-cov-2 virus immunogenic compositions, methods of making and using
WO2024073860A1 (en) * 2022-10-07 2024-04-11 Elarex Inc. Stabilization of virus-based therapeutic agent

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2505657A1 (fr) 1981-05-13 1982-11-19 Pasteur Institut Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation
FR2742756B1 (fr) * 1995-12-22 1998-04-03 Pasteur Merieux Serums Vacc Stabilisants pour vaccins vivants, vaccins les contenant et procedes pour leur preparation
US6616931B1 (en) 1996-09-26 2003-09-09 Merck & Co., Inc. Rotavirus vaccine formulations
JP2001511459A (ja) * 1997-07-31 2001-08-14 ハワイ バイオテクノロジー グループ， インコーポレイテッド フラビウイルス感染に対抗する組換え二量体エンベロープワクチン
US6210683B1 (en) * 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
US6163606A (en) * 1998-09-16 2000-12-19 Lucent Technologies Inc. System for providing virtual called party identification in a voice mail system
CN1053590C (zh) 1998-10-19 2000-06-21 卫生部长春生物制品研究所 冻干甲型肝炎减毒活疫苗及其保护剂
CN1062770C (zh) * 1998-11-12 2001-03-07 卫生部长春生物制品研究所 甲肝-麻疹二联疫苗及其生产方法
BR0010249A (pt) 1999-05-04 2002-02-13 Eric Edward Worrall Processo para a preservação de vìrus e micoplasma
US6432411B1 (en) * 1999-07-13 2002-08-13 Hawaii Biotechnology Group Recombinant envelope vaccine against flavivirus infection
CA2941182A1 (en) * 2000-02-16 2001-08-23 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Avirulent, immunogenic flavivirus chimeras
AT410634B (de) * 2001-02-21 2003-06-25 Franz X Dr Heinz Attenuierte lebendimpfstoffe
EP1453536A4 (en) 2001-12-12 2009-08-26 Mayne Pharma Int Pty Ltd COMPOSITION FOR PRESERVING VIRUSES
WO2003102166A2 (en) * 2002-02-26 2003-12-11 Maxygen, Inc. Novel flavivirus antigens
US8293530B2 (en) 2006-10-17 2012-10-23 Carnegie Mellon University Method and apparatus for manufacturing plasma based plastics and bioplastics produced therefrom
US20040042972A1 (en) * 2002-04-11 2004-03-04 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
EP2591771A1 (en) * 2002-04-11 2013-05-15 MedImmune, LLC Preservation of bioactive materials by freeze dried foam
DE60231661D1 (es) 2002-04-15 2009-04-30 Tetsuo Santo
GB0302218D0 (en) * 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
US6873807B2 (en) * 2003-03-20 2005-03-29 Kabushiki Kaisha Toshiba Image forming apparatus
US7588774B2 (en) * 2003-05-12 2009-09-15 Becton, Dickinson And Company Molecules enhancing dermal delivery of influenza vaccines
US7294455B2 (en) 2003-05-16 2007-11-13 The University Of North Carolina At Chapel Hill Fixed-dried platelets cross-linked to protein
EP1708742A4 (en) * 2003-12-05 2008-11-05 Becton Dickinson Co METHOD FOR IMPROVING THE IMMUNE RESPONSE IN THE INTRADERMAL COMPARTMENT AND USEFUL LINKS THEREFOR
US20050202046A1 (en) 2004-03-11 2005-09-15 Wyeth Canine vaccine for protection against ehrlichiosis
US20050276785A1 (en) * 2004-06-09 2005-12-15 Schering Aktiengesellschaft Treatment of cardiomyopathy and of endothelial dysfunction
EP1645283A1 (en) * 2004-10-08 2006-04-12 Chiron Behring GmbH & Co. KG Combination vaccine
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
KR102134980B1 (ko) * 2007-04-06 2020-07-16 다케다 백신즈 인코포레이티드 살아있는 약독화된 바이러스를 위한 방법 및 조성물

Also Published As

Publication number Publication date
IL201429A0 (en) 2011-08-01
EP2144998A4 (en) 2011-11-02
BRPI0809663B8 (pt) 2021-05-25
MX2009010798A (es) 2010-02-18
PH12015500773B1 (en) 2017-08-07
ZA200907790B (en) 2014-04-30
CY1118958T1 (el) 2018-01-10
KR101562971B1 (ko) 2015-10-23
DK2144998T3 (en) 2017-04-10
IL248522A0 (en) 2016-12-29
US20200108136A1 (en) 2020-04-09
CN104998257A (zh) 2015-10-28
US11197923B2 (en) 2021-12-14
KR102134980B1 (ko) 2020-07-16
ES2621511T3 (es) 2017-07-04
SG10201508397VA (en) 2015-11-27
EP2940129B1 (en) 2020-05-06
EP2144998A1 (en) 2010-01-20
JP2016041753A (ja) 2016-03-31
US8084039B2 (en) 2011-12-27
JP6817370B2 (ja) 2021-01-20
IL228065A0 (en) 2013-09-30
JP2013209421A (ja) 2013-10-10
KR20100016294A (ko) 2010-02-12
PL2144998T3 (pl) 2017-07-31
LT2144998T (lt) 2017-04-25
MX360728B (es) 2018-11-14
HK1217168A1 (zh) 2016-12-30
WO2009014774A1 (en) 2009-01-29
PH12015500773A1 (en) 2017-08-07
AU2008279576A1 (en) 2009-01-29
KR20150082667A (ko) 2015-07-15
AU2008279576C1 (en) 2014-01-23
JP5296775B2 (ja) 2013-09-25
IL248522B (en) 2019-11-28
EP2144998B1 (en) 2017-01-04
IL228065B (en) 2019-05-30
NZ580978A (en) 2012-07-27
MY180465A (en) 2020-11-30
CN110478479B (zh) 2024-09-03
ZA201400725B (en) 2022-11-30
CN110478479A (zh) 2019-11-22
KR20170038110A (ko) 2017-04-05
JP2010523127A (ja) 2010-07-15
CN104083757A (zh) 2014-10-08
IL201429A (en) 2013-09-30
JP2019172686A (ja) 2019-10-10
BRPI0809663B1 (pt) 2020-02-11
PT2144998T (pt) 2017-04-07
US20170100474A1 (en) 2017-04-13
CA2720570A1 (en) 2009-01-29
BRPI0809663A8 (pt) 2017-07-11
US20080248551A1 (en) 2008-10-09
NZ600958A (en) 2015-05-29
HK1140516A1 (zh) 2010-10-15
HRP20170513T1 (hr) 2017-06-02
SG10201913741YA (en) 2020-03-30
BRPI0809663A2 (pt) 2014-10-14
SI2144998T1 (sl) 2017-05-31
AU2008279576B2 (en) 2013-08-22
EP2940129A1 (en) 2015-11-04
MY156422A (en) 2016-02-26
HUE031617T2 (en) 2017-07-28
KR20180036801A (ko) 2018-04-09
US10525120B2 (en) 2020-01-07
US20140302091A1 (en) 2014-10-09
CA2720570C (en) 2022-10-04
CN101679954A (zh) 2010-03-24
CO6260150A2 (es) 2011-03-22

Similar Documents

Publication Publication Date Title
CU20090169A7 (es) Métodos y composiciones para virus vivos atenuados
AR068363A1 (es) Reduccion de infecciones concomitantes en cerdos mediante el uso de antigeno pcv2
AR063606A1 (es) Estabilizacion de vacunas mediante liofilizacion
UY29915A1 (es) Vacuna combinada que comprende un virus atenuado de la diarrea viral bovina
CL2009002207A1 (es) Compuestos derivados de 3-hidroxi-5-(9h-purin-9-il)tetrahidrofuran-2-il, inhibidor de la replicacion de arn viral dependiente de arn; composicion farmaceutica; uso para el tratamiento de hepatitis c.
ECSP14013315A (es) Inhibidores de aplicación viral
UY32721A (es) Composiciones farmacéuticas útiles para tratar el virus de la hepatitis c (vhc), usos y métodos relacionados
AR069882A1 (es) Circovirus porcino, molecula de acido nucleico aislada que lo codifica, composicion inmunogenica que lo comprende, vector que comprende por lo menos una molecula de acido nucleico exogena que codifica una proteina de circovirus porcino y metodos para inmunizar un cerdo contra la infeccion virica o e
UY32715A (es) Combinaciones farmacéuticas útiles para el tratamiento del virus de la hepatitis c (vhc), usos y métodos relacionados
BRPI1013780A2 (pt) composições para imunização contra staphylococcus aureus.
UY32720A (es) Combinaciones farmaceuticas utiles para el tratamiento del virus de la hepatitis c (vhc), usos y metodos relacionados
AR065319A1 (es) Prevencion y tratamiento de pcvd subclinica
CU24701B1 (es) Composiciones de vacuna estables que comprenden inter alia un flavivirus recombinante vivo atenuado y proceso para la preparación de las mismas
CL2011001993A1 (es) Composicion inmunogenica que comprende al menos un antigeno del virus del dengue inactivado y un adyuvante sin aluminio; metodo de produccion; y su uso para prevenir, mejorar o tratar una enfermedad productiva por el virus del dengue en un sujeto.
CL2013001877A1 (es) Composicion inmunogenica que comprende un virus de diarrea viral bovina tipo 1b vivo modificado y un portador veterinario aceptable; vacuna que la comprende; y su uso para prevenir, tratar, manejar o aliviar uno o mas sintomas de una enfermedad causada por pestivirus.
ECSP20007842A (es) Composiciones y métodos para formulaciones de alfavirus vivos atenuados
WO2017156511A8 (en) Live attenuated zika virus vaccine
PH12016500465A1 (en) Deoxynojirimycin derivatives and methods of their using
CL2016000300A1 (es) Métodos terapéuticos
AR101814A1 (es) Partícula de tipo virus flavivirus
CL2018001946A1 (es) Virus atenuados de bronquitis infecciosa.
CO7461135A2 (es) Parvovirus porcino 5b, métodos de uso y vacuna
BR112015031226A2 (pt) Composição de vacina, e, uso da composição de vacina
CL2017001595A1 (es) Composiciones de vacuna para el virus del dengue y métodos de uso de las mismas
AR074483A1 (es) Composiciones, metodos y usos para inducir al crecimiento viral